Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Nintedanib on Microgynon PK in SSc-ILD
NCT03675581Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2018
- Primary completion
- Oct 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Ethinylestradiol in Plasma from 0 to Last Quantifiable Data Point at 48 hours, Area Under the Concentration-time Curve of Levonorgestrel in Plasma from 0 to Last Quantifiable Data Point at 48 hours and 2 more. Started Nov 2018; status: completed.
02
Drugs
nintedanib
03
Conditions
systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT03675581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675581.